Clinical trials: Hair Problems
Alopecia Totalis/Universalis, Alopecia Areata(AA)
Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation
The goal of this observational study is to evaluate safety of Rhofanib® (Tofacitinib) in male or female participants with the age of 18 years or older having clinical diagnosis of Alopecia.
- Trial name
- NCT07101471
- Testing
- Tofacitinib
- Where
- Iran
- Volunteers
- 296 people
- Sponsor
- NanoAlvand
Severe Alopecia Areata
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe alopecia areata. Alopecia areata is a condition that causes hair loss.
- Trial name
- B7981027 (NCT07029711)
- Testing
- Ritlecitinib higher dose, Ritlecitinib lower dose
- Where
- 83 sites in United States, China and 7 more
- Volunteers
- 208 people
- Sponsor
- Pfizer
Androgenetic Alopecia
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
- Trial name
- NCT04945226
- Testing
- Finasteride 1mg Tablet, IVL3001
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Inventage Lab., Inc.
Hair Thinning
A Safety and Efficacy Study of a Nutraceutical in Aging Males With Thinning Hair
A study to assess the safety and efficacy of a dietary supplement when used over the course of 9 months by men with self-perceived hair thinning.
- Trial name
- NCT06854575
- Testing
- Dietary Supplement
- Where
- 3 sites in United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Nutraceutical Wellness Inc.
Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men
A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe
Androcur is a type of treatment called cyproterone acetate (CPA). Androcur and other CPA treatments work by blocking a group of male sex hormones called androgens in the body.
- Conditions
- Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea, Hypersexuality in Men, Sexual Deviations in Men, Prostate Cancer
- Trial name
- Safe-CAM (NCT04925180)
- Testing
- Cyproterone Acetate (Androcur, BAY94-8367)
- Where
- 5 sites in France, Germany and 3 more
- Volunteers
- 600 people
- Sponsor
- Bayer
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)
Evaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01669746
- Testing
- Autologous cultured mixed population of dermal cells
- Where
- 7 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Hypotrichosis
Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation
Study to Evaluate the safety and efficacy of a Latanoprost/Minoxidil formulation vs. placebo for the treatment of hypotrichosis of the eyebrows.
- Trial name
- NCT05790941
- Testing
- Latanoprost and Minoxidil
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Aneira Pharma, Inc.
Female Pattern Hair Loss, Androgenic Alopecia
Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia
The purpose of this study is to characterize the effect of Minoxidil 2% Solution and Botanical Hair Solution Regimen in women with thinning hair and female pattern hair loss/androgenic alopecia (Ludwig I and II).
- Trial name
- NCT02460497
- Testing
- Treatment: Minoxidil 2% / Botanical Hair Solution for Women
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Galderma R&D
Neoplasms, Alopecia
START: Swiss Taxotere Alopecia Prevention Trial
Primary objective: Rate of complete chemotherapy induced alopecia (WHO grade III or IV, physician grading) Secondary objective: Compliance to scalp cooling procedure Received number of cycles of chemotherapy in each subgroup…
- Trial name
- NCT01008774
- Testing
- Paxman Cooling Machine, Cold Caps
- Where
- Switzerland
- Volunteers
- 239 people
- Sponsor
- Sanofi
Alopecia, Sensitive Skin
A Scalp Lotion Toimprove Sensitive Scalp Syndrome
Overall, 100 Caucasian subjects participated in this 6-weeks lasting study, AC5+ was applied daily. All subjects had clinically confirmed mild to moderate alopecia and self-declared sensitive scalp.
- Trial name
- NCT05630027
- Testing
- Piroctone Olamine (PO), 2,4 Diaminopyrimidine oxide (2.4 DA) and Vichy mineralizing water
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Cosmetique Active International
Hair Loss
Evaluation of the Performance of a Nutricosmetic on Hair & Scalp in Women and Men After 3 and 6 Months
In order to validate the product performance, L'Oréal R\&I decided to conduct a new clinical study. The final product is intended to be performant in men and women.
- Trial name
- NCT07556016
- Testing
- Active nutricosmetic
- Where
- 4 sites in France
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- L'Oreal
Androgenetic Alopecia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia.
- Trial name
- NCT01231607
- Testing
- 1mg Finasteride active, 0.02mg dutasteride, 0.1mg dutasteride
- Where
- 39 sites in Argentina, Chile and 7 more
- Volunteers
- 917 people
- Sponsor
- GlaxoSmithKline
Androgenetic Alopecia, Hair Loss
Treatment of Androgenetic Alopecia in Females, 9 Beam
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 9 beam model in promoting hair growth in females diagnosed with androgenetic alopecia when treatment is applied as directed.
- Conditions
- Androgenetic Alopecia, Hair Loss, Female Pattern Baldness
- Trial name
- NCT00981461
- Testing
- HairMax LaserComb, Control Device
- Where
- 5 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Alopecia, Alopecia, Androgenetic
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia.
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT01325337
- Testing
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
- Where
- 2 sites in United States, Germany
- Volunteers
- 307 people
- Sponsor
- Allergan
Androgenetic Alopecia
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK.
- Trial name
- NCT06393452
- Testing
- PP405 0.05% Topical Gel, Topical Vehicle Gel
- Where
- 8 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Pelage Pharmaceuticals, Inc.
Androgenetic Alopecia
Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers
This clinical study is designed to evaluate the efficacy and safety of a dietary supplement CL-P24113a for the management of androgenetic alopecia (AGA) in male subjects aged 18 to 45 years who suffer from alopecia with low hair…
- Trial name
- NCT06841458
- Testing
- Oral Supplement
- Where
- 2 sites in Spain
- Volunteers
- 45 people
- Sponsor
- Industrial Farmacéutica Cantabria, S.A.
Alopecia Areata
Evaluation of the Effect of Topical Calcipotriol Versus Platelet-Rich Plasma
Alopecia areata (AA) is a common, immune-mediated non scarring alopecia and can be associated with severe psychological consequences . Alopecia Areata affects 2% of the global population.
- Trial name
- NCT05954104
- Testing
- Calcipotriol
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Egymedicalpedia
Androgenetic Alopecia
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
- Trial name
- NCT06916793
- Testing
- CKD-843 dose#1, CKD-843 dose#2, Dutasteride Capsules
- Where
- South Korea
- Volunteers
- 288 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Alopecia Areata, Alopecia
Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe AA.
- Conditions
- Alopecia Areata, Alopecia, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT05589610
- Testing
- EQ101
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 36 people
- Sponsor
- Equillium
Androgenetic Alopecia
XVIE to Treat Androgenetic Alopecia (AGA)
This study tests whether XVIE, an investigational injectable product made from processed human amniotic fluid, is safe and may help regrow hair in adults with androgenetic alopecia (common pattern hair loss).
- Trial name
- NCT07482423
- Testing
- Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé